Cargando…

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

We report an analysis of the propensity of the antimalarial agent cabamiquine, a Plasmodium-specific eukaryotic elongation factor 2 inhibitor, to select for resistant Plasmodium falciparum parasites. Through in vitro studies of laboratory strains and clinical isolates, a humanized mouse model, and v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stadler, Eva, Maiga, Mohamed, Friedrich, Lukas, Thathy, Vandana, Demarta-Gatsi, Claudia, Dara, Antoine, Sogore, Fanta, Striepen, Josefine, Oeuvray, Claude, Djimdé, Abdoulaye A., Lee, Marcus C. S., Dembélé, Laurent, Fidock, David A., Khoury, David S., Spangenberg, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457284/ https://www.ncbi.nlm.nih.gov/pubmed/37626093 http://dx.doi.org/10.1038/s41467-023-40974-8

Ejemplares similares

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs
por: Dembele, Laurent, et al.
Publicado: (2023)

Comparative Susceptibility of Plasmodium ovale and Plasmodium falciparum Field Isolates to Reference and Lead Candidate Antimalarial Drugs in Ghana
por: Aniweh, Yaw, et al.
Publicado: (2023)

Ex Vivo Plasmodium malariae Culture Method for Antimalarial Drugs Screen in the Field
por: Dembele, Laurent, et al.
Publicado: (2021)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

The Prevalence of Human Plasmodium Species during Peak Transmission Seasons from 2016 to 2021 in the Rural Commune of Ntjiba, Mali
por: Dao, Francois, et al.
Publicado: (2023)

Antimalarial stewardship programs are urgently needed for malaria elimination: a perspective
por: Bienvenu, Anne-Lise, et al.
Publicado: (2019)

Vector saliva controlled inflammatory response of the host may represent the Achilles heel during pathogen transmission
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2021)

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022)

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
por: de Vries, Laura E., et al.
Publicado: (2022)

Hands-on training in structural biology, a tool for sustainable development in Africa series 4
por: Ouologuem, Dinkorma T., et al.
Publicado: (2022)

Fahr's syndrome with hyperparathyroidism revealed by seizures and proximal weakness
por: Dembélé, Kékouta, et al.
Publicado: (2019)

Antimalarial drug discovery: progress and approaches
por: Siqueira-Neto, Jair L, et al.
Publicado: (2023)

Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents
por: Stokes, Barbara H., et al.
Publicado: (2019)

Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia
por: Ménard, Didier, et al.
Publicado: (2019)

Immunological memory to blood-stage malaria infection is controlled by the histamine releasing factor (HRF) of the parasite
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2017)

Using Cryopreserved Plasmodium falciparum Sporozoites in a Humanized Mouse Model to Study Early Malaria Infection Processes and Test Prophylactic Treatments
por: Jiménez-Díaz, María-Belén, et al.
Publicado: (2023)

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2023)

Syndrome de Kartagener de découverte fortuite au cours d'un bilan d'infécondité du couple à propos d'un cas
por: Doumbia, Amadou, et al.
Publicado: (2019)

Gametocyte clearance dynamics following oral artesunate treatment of uncomplicated falciparum malaria in Malian children
por: Djimde, Abdoulaye A., et al.
Publicado: (2016)

Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali
por: Dama, Souleymane, et al.
Publicado: (2017)

Malarial PI4K inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition
por: Demarta‐Gatsi, Claudia, et al.
Publicado: (2022)

Expansion of a Specific Plasmodium falciparum PfMDR1 Haplotype in Southeast Asia with Increased Substrate Transport
por: Calçada, Carla, et al.
Publicado: (2020)

A Novel Ex Vivo Drug Assay for Assessing the Transmission-Blocking Activity of Compounds on Field-Isolated Plasmodium falciparum Gametocytes
por: Ouologuem, Dinkorma T., et al.
Publicado: (2022)

Malaria Parasite-Infected Erythrocytes Secrete PfCK1, the Plasmodium Homologue of the Pleiotropic Protein Kinase Casein Kinase 1
por: Dorin-Semblat, Dominique, et al.
Publicado: (2015)

Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study
por: McCarthy, James S, et al.
Publicado: (2021)

Plasmodium falciparum Development from Gametocyte to Oocyst: Insight from Functional Studies
por: Ouologuem, Dinkorma T., et al.
Publicado: (2023)

Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali
por: Tekete, Mamadou, et al.
Publicado: (2009)

Antimalarial drug discovery – the path towards eradication
por: BURROWS, JEREMY N, et al.
Publicado: (2014)

Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery
por: Murithi, James M., et al.
Publicado: (2020)

Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in Mali
por: Maiga, Hamma, et al.
Publicado: (2015)

Cavernomatose cérébrale sporadique révélée par une crise convulsive: à propos d’un cas
por: Amadou, Doumbia, et al.
Publicado: (2018)

Surveillance of Travellers: An Additional Tool for Tracking Antimalarial Drug Resistance in Endemic Countries
por: Gharbi, Myriam, et al.
Publicado: (2013)

Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials
por: Wicht, Kathryn J, et al.
Publicado: (2022)

An affordable antimalarial.
por: Tenenbaum, David J
Publicado: (2004)

Synthesis and Antimalarial Activity of 1,4-Disubstituted Piperidine Derivatives
por: Seck, Rokhyatou, et al.
Publicado: (2020)

Impact of Three-Year Intermittent Preventive Treatment Using Artemisinin-Based Combination Therapies on Malaria Morbidity in Malian Schoolchildren
por: Maiga, Hamma, et al.
Publicado: (2020)

SARS-CoV-2 seroprevalence and living conditions in Bamako (Mali): a cross-sectional multistage household survey after the first epidemic wave, 2020
por: Cissoko, Mady, et al.
Publicado: (2023)

Prioritization of Molecular Targets for Antimalarial Drug Discovery
por: Forte, Barbara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jv7rfrafqmhg011pollld422dk